Page 52 - 林口醫研部 9月電子報
P. 52
‣應用性
此研究顯示，以PRKDC突變作為篩選標的可以有效提高免疫檢查點
抑制劑療法成功率，此發現將有助於篩選出適合免疫檢查點抑制劑療法
的病人，嘉惠全球的病人，可做為醫療照顧政策的重要參考。
‣圖表
•Figure 1. Comparison of PRKDC mutation and MSI status, and immune
signatures. Proportions and enrichment between patients with PRKDC
mutations and MSI-H in the dataset of patients with TCGA gastric cancer(A),
colorectal cancer(B).
MSI, microsatellite instability; MSI-H, microsatellite instability—high; MSI-L,
microsatellite instability—low; MSS, microsatellite stable; MT, mutant;
PRKDC, protein kinase, DNA-activated, catalytic polypeptide; TCGA, The
Cancer Genome Atlas; WT, wild type.
52
